Nadunolimab is a human monoclonal Gemcitabine .
Blocked both murine IL-1α and IL-1β signaling.
[1]. Rydberg Millrud C, et, al. Blockade of IL-1α and IL-1β signaling by the anti-IL1RAP antibody nadunolimab (CAN04) mediates synergistic anti-tumor efficacy with chemotherapy. Cancer Immunol Immunother. 2022 Aug 29.
















